Cargando…

Increased Oxidative Damage in Carriers of the Germline TP53 p.R337H Mutation

Germline mutations in TP53 are the underlying defect of Li-Fraumeni Syndrome (LFS) and Li-Fraumeni-like (LFL) Syndrome, autosomal dominant disorders characterized by predisposition to multiple early onset cancers. In Brazil, a variant form of LFS/LFL is commonly detected because of the high prevalen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macedo, Gabriel S., Lisbôa da Motta, Leonardo, Giacomazzi, Juliana, Netto, Cristina B. O., Manfredini, Vanusa, S.Vanzin, Camila, Vargas, Carmen Regla, Hainaut, Pierre, Klamt, Fábio, Ashton-Prolla, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467233/ https://www.ncbi.nlm.nih.gov/pubmed/23056559 http://dx.doi.org/10.1371/journal.pone.0047010

Ejemplares similares

TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient
por: Giacomazzi, Juliana, et al.
Publicado: (2013)

Comparison of multiple genotyping methods for the identification of the cancer predisposing founder mutation p.R337H inTP53
por: Fitarelli-Kiehl, Mariana, et al.
Publicado: (2016)

Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil
por: Giacomazzi, Juliana, et al.
Publicado: (2014)

Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p
por: Paskulin, Diego Davila, et al.
Publicado: (2015)

Occurrence of Neuroblastoma among TP53 p.R337H Carriers
por: Seidinger, Ana Luiza, et al.
Publicado: (2015)

TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients
por: Hahn, Eriza Cristina, et al.
Publicado: (2018)

Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers
por: Gerber, Viviane K. Q., et al.
Publicado: (2022)

Modeling the prevalent germline TP53 R337H mutation in mouse
por: Park, Ji-Hoon, et al.
Publicado: (2019)

Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome
por: Sandoval, Renata Lazari, et al.
Publicado: (2021)

Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility
por: Pinto, Emilia M., et al.
Publicado: (2023)

TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child - evidence for chimerism involving a common mutant founder haplotype: case report
por: da Silva, Edaise M, et al.
Publicado: (2011)

Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?
por: Vieira, Igor Araujo, et al.
Publicado: (2021)

Association of the germline TP53 R337H mutation with breast cancer in southern Brazil
por: Assumpção, Juliana G, et al.
Publicado: (2011)

Association of the germline TP53 R337H mutation with breast cancer in southern Brazil
por: Assumpção, Juliana G, et al.
Publicado: (2008)

Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 p.R337H Carriers
por: Sandoval, Renata Lazari, et al.
Publicado: (2022)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families
por: Cury, Nathalia M, et al.
Publicado: (2014)

What 20 years of research has taught us about the TP53 p.R337H mutation
por: Pinto, Emilia Modolo, et al.
Publicado: (2020)

Increased Incidence of Choroid Plexus Carcinoma Due to the Germline TP53 R337H Mutation in Southern Brazil
por: Custodio, Gislaine, et al.
Publicado: (2011)

The Brazilian TP53 mutation (R337H) and sarcomas
por: Volc, Sahlua Miguel, et al.
Publicado: (2020)

Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p.R337H mutation
por: Andrade, Kelvin C., et al.
Publicado: (2016)

The R337H mutation in TP53 and breast cancer in Brazil
por: Gomes, Magda CB, et al.
Publicado: (2012)

The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis
por: Lopes, Carlos D. H., et al.
Publicado: (2023)

Prevalence and impact of founder mutations in hereditary breast cancer in Latin America
por: Ashton-Prolla, Patricia, et al.
Publicado: (2014)

TP53 PIN3 and PEX4 polymorphisms and infertility associated with endometriosis or with post-in vitro fertilization implantation failure
por: Paskulin, D D, et al.
Publicado: (2012)

Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2016)

TP53 p.Arg337His geographic distribution correlates with adrenocortical tumor occurrence
por: Seidinger, Ana L., et al.
Publicado: (2020)

Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark
por: Stoltze, Ulrik, et al.
Publicado: (2018)

Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability
por: Mathias, Carolina, et al.
Publicado: (2020)

Health Tract No. 337: Architects
Publicado: (1868)

The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations
por: Silva, Amanda G, et al.
Publicado: (2014)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis
por: Kratz, Christian P., et al.
Publicado: (2021)

Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53
por: Omran, Meis, et al.
Publicado: (2020)

337 Innovation Opportunities within Lymphedema
por: Plona, Zachary, et al.
Publicado: (2022)

Germline mutation in the TP53 gene in uveal melanoma
por: Hajkova, Nikola, et al.
Publicado: (2018)

Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)
por: Packwood, Kate, et al.
Publicado: (2019)

TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review
por: Rosset, Clévia, et al.
Publicado: (2017)

Newborn Screening for the Detection of the TP53 R337H Variant and Surveillance for Early Diagnosis of Pediatric Adrenocortical Tumors: Lessons Learned and Way Forward
por: Tosin, Karina C. F., et al.
Publicado: (2021)

Germline TP53 mutations in Finnish breast cancer patients
por: Rapakko, K, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_bi9i6510m7rhka1187lk9fact9